Outcomes of pulmonary resection in non-small cell lung cancer Outcomes of pulmonary resection in non-small cell lung cancer patients older than 70 years old patients older than 70 years old Summary Background: An appropriate treatment of older lung cancer patients has become an important issue. The aim of this study is to evaluate the short and long-term surgical outcomes in lung cancer patients using 70 years as a cut-point, and to identify prognostic factors of cancer-specific mortality in patients older than 70 years. Methods: Medical records of non-small cell lung cancer (NSCLC) patients who underwent pulmonary resection at Chiang Mai University Hospital from January 2002 through December 2016 were retrospectively reviewed. Patients were divided into age less than 70 years (control group) and 70 years or more (study group). Primary outcomes were major post-operative complications and in-hospital death (POM); secondary outcome was long-term survival. 
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Introduction
Surgical treatment is the standard of care with curative intent in early stage non-small cell lung cancer (NSCLC) patients, but also for symptomatic treatment in advanced disease. Nowadays, because of increasing in life span, and more than one-third of lung cancer patients being age >70 years old, 1,2 defining the appropriate treatment of elderly lung cancer patients has become an important issue in terms of perioperative morbidity, mortality and overall survival. Because of physiological changes in the cardiovascular and pulmonary function in elderly patients, morbidity and mortality after pulmonary resection should be a concern. Previous studies reported that there are approximately 30e50% postoperative complications in elderly NSCLC patients, 3e5 therefore alternative treatment strategies and surgical techniques were developed for avoiding postoperative complications such as stereotactic body radiotherapy, and minimally invasive approach. 6e8 Although previous studies demonstrated excellent outcomes with acceptable postoperative morbidity and mortality in elderly patients after either sublobar resection or lobectomy, 2,9,10 some studies report worse short-term and long-term outcomes in elderly patients (age!70 years) in comparison to younger ones. 11 In this study, we retrospectively reviewed data on NSCLC patients who underwent curative pulmonary resection to analyze the short and longterm surgical outcomes comparing between patients age <70 years and age !70 years, to determine the impact of age on long-term survival and to identify prognostic factors of long-term cancer-specific mortality in patients age more than 70 years.
Patients and methods
This is a retrospective cohort study. Medical records of nonsmall cell lung cancer (NSCLC) patients who underwent pulmonary resection (either curative or palliative intent) with systematic mediastinal lymph node dissection or sampling in the general thoracic surgery unit, department of surgery, faculty of medicine, Chiang Mai university, Chiang Mai, Thailand between January 2002 to June 2015 were retrospectively reviewed. Clinical characteristics including age, gender, history of smoking, family history of cancer, comorbidities, patient physical status, laboratory findings, pre-operative cardiac and pulmonary function testing, surgery information, pathologic report and postoperative outcomes were extracted. The cut-of-point for age is debatable, however, according to previous studies, 12e15 we used the age of 70 years to divide all eligible patients into two groups; study group (age ! 70 years) and control group (age <70 years). The primary outcome was composite: major postoperative complication (POM) (including in-hospital mortality, pneumonia, acute respiratory distress syndrome (ARDS), intubation more than 24 h after surgery (delayed extubation), re-intubation, tracheostomy, atelectasis needing bronchoscopy and prolonged air leak more than 5 days according to STS GTDB guidelines. 16 The secondary outcomes were length of hospital stay, long-term cancer-specific mortality, and tumor recurrence. This study was reviewed and approved by the Institutional Review Board of Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand with Study Code: SUR-2558-033491/Research ID: 3349, and approval ID 434/2015.
All patients received preoperative cancer staging including computed tomography (CT) with contrast or whole-body positron emission tomography, bronchoscopy with biopsy, bronchial washing, brushing or bronchial lavage cytology. If mediastinal lymph nodes were larger than 1 cm, endobronchial ultrasound-guided (EBUS) fine needle aspiration, or mediastinoscope biopsy were performed. All patients had a biochemistry profile, a pulmonary function test, a room-air arterial blood gas, and an electrocardiography.
The pulmonary resections included wedge, segmentectomy, lobectomy and pneumonectomy, both for curative intent or palliative resection. The indication for sublobar resection (wedge resection or segmentectomy) included patients who had maximum tumor size less than 2 cm and severe comorbid diseases or poor-pulmonary reserved function according to American College of Chest Physicians Evidence-Based Clinical Practice Guideline. 17 Surgical approaches included open thoracotomy and video-assisted thoracoscopic approach (VATS). Systematic mediastinal lymph node dissection (SLND) or sampling (SLNS) were performed in all cases. According to European Society of Thoracic Surgeons guidelines, systematic mediastinal lymph node dissection is to dissect and remove all mediastinal tissue containing the lymph nodes within anatomic landmark at least three mediastinal nodal stations, including the subcarinal node. Systematic mediastinal lymph node sampling means a lesser excision of certain nodal stations that seem to be representative or abnormal in preoperative evaluations or intraoperative. 18 Lymph node mapping was issued by International Association for the Study of Lung Cancer (IASLC), original by Naruke et al. 19 Lymph node ratio was calculated by the proportion of positive dissected lymph node over the total number of dissected lymph node. Tumor staging was reviewed according to the 8th edition of the TNM classification for lung cancer issued by (IASLC). 20 After discharge, patients were followed up at 2 weeks and 1e2 months with CXR and physical examination, and then every 3 months for the first two years and then every 6 months with CT-scan. When tumor recurrence was suspected, diagnostic procedures were performed to confirm the diagnosis either with cytology or diagnostic radiology. Patients received chemotherapy and/or radiotherapy according to their performance status and tumor status. The regimens of chemotherapy included cisplatin, carboplatin, vinorelbine, vinorelbine, gemcitabine, docetaxel, pemetrexed and targeted therapy (erlotinib, gefitinib, crizotinib) depending on molecular testing and insurance coverage. Overall survival and recurrence-free survival were calculated from the date of surgery to the most recent follow-up contact or to the date of death, and from the date of first tumor diagnosis to either local recurrence or distant metastasis, respectively.
Statistical analysis
categorical variables were presented as frequency and proportion (%); continuous variables were presented as mean AE standard deviation (SD) or median AE interquartile range (IQR) depending on the data distribution. When the two groups were compared, Fisher exact test was used for categorical data and unpaired student t-test or Wilcoxon rank sum test for continuous variables. Univariable and multivariable logistic regression analysis were used to identify risk factors of POM and presented with odd ratios and 95% confidence intervals; matching propensity score was also performed and showed in the supplement data. Multiple imputations with multivariate normal equation were performed for any variables with at least 10% missing values. 21 We then compared the results from a completecase analysis with the results of multiple imputations (MI) analysis. Cox proportional hazard model was used to assess prognostic factors of recurrence of disease and long-term survival, which were presented as hazard ratios with 95% confidence interval. Any risk factors or prognostic factors with p value < 0.1 in the univariable analyses and other potential clinical confounders associated with POM, tumor recurrence, and long-term survival were included in the multivariable analysis model. Multicollinearity of independent factors was tested before performing multivariable analysis. Patients with stage IV disease were excluded when analyzing for prognostic factors for tumor recurrence. The statistical analysis was completed in STATA statistical package (Release 15.1,2018; StataCorp, CS, TX, USA), with p < 0.05 indicating a statistically significant difference.
Results
There were 583 patients diagnosed with NSCLC who underwent curative or palliative pulmonary resection enrolled in this study, 167 in study group and 416 in control group. The mean age was 62.4 AE 10.4 years (range from 18 to 86 years), 74.5 AE 4.0 years in the study group and 57.5 AE 8.0 years in the control group. Their demographics, preoperative characteristics, and pathologic results are shown in Table 1 . There were 36 patients diagnosed stage IVA who underwent pulmonary resection; 20 patients presented with single brain metastasis and received whole brain radiation or excision and 16 patients had single lung to lung metastasis. Patients in the study group were more likely to have the civil servant medical benefit scheme, be active smoker, have a higher number of pack-year of smoking, COPD, HT, dyslipidemia, abnormal preoperative ECG than patients in the control group. There were no statistically significant differences in gender, body mass index, preoperative pulmonary function test, ejection fraction, tumor stage and pathologic findings between the two groups. Patients in the study group were more likely to undergo sublobar resection (wedge resection or segmentectomy), SLNS, and to die in hospital, whereas less likely to receive chemotherapy (either adjuvant or neoadjuvant regimen), and to be immediately extubated after surgery than those in the control group (Table 2 ). There were no statistically significant differences in term of approach (VATS or open thoracotomy), lymph node ratio, operative time, estimated blood loss, and length of intensive care unit stay between the two groups. Postoperative complications, major complications, and overall mortality were not different between the two groups. However, in-hospital mortality, postoperative arrythmia, air leak, acute renal failure and other minor complications were documented more often among patients in the study group than the control group. The most common postoperative complication in both groups was postoperative air leak; these patients only had forced expiratory air leak and success for conservative treatment. The incidence of postoperative acute renal failure in the study group was higher than in the control group (2.5% versus 0.5%, p Z 0.059). Patients in the study group had shorter follow-up time than the control group. In a subgroup analysis according to stage, patients in the study group were more likely to undergo sublobar resection than those in the control group; however, only stage IA3 patients showed a statistically significant difference between the two groups (Supplement A).
POM was not statistically different between the two groups. The adjusted Odds Ratio for study group compared to the control group was 0.89 (95% confidence interval (CI) Z 0.43e1.84) ( Table 3) . Tumor recurrence was not statistically significant different between groups, while long-term cancer-specific mortality was: patients in the study group had shorter longterm survival than those in the control group (Fig. 1) . In multivariable analysis, the adjusted hazard ratio (HR adj ) for tumor recurrence in the study group compared to the In additional analysis, we perform matching (1:1) propensity score (PS) which was calculated by logistic regression. The variables included in the model for PS were gender, insurance status, number of pack year of smoking, COPD, DM, hypertension, dyslipidemia, preoperative ECG finding, histology, tumor stage, intratumoral lymphatic invasion, intratumoral vessel invasion, perineural invasion, tumor necrosis, surgical approach, surgical procedures, type of lymph node dissection, and chemotherapy. After matching, 153 patients were included in both groups. There were no statistically significant differences in term of patient characteristics, pulmonary function test, histologic findings, tumor staging, pathologic findings, surgical procedures, surgical approaches, lymphatic dissection, and induction chemotherapy between the two groups. Hypertension was significant higher in the study group (Appendix B). There were 6 patients died after surgery in the study group; caused by multiple postoperative complications such as pneumonia, septicemia, or acute respiratory distress syndrome. ICU stay was significantly longer in the study group. Long-term cancer-specific mortality was significant higher in the study group (Appendix C). In multivariable analysis, there were no significant difference in term of ICU stay, composite major postoperative complications, and tumor recurrence between the two groups. However, patients in the study group were more likely to die (long-term cancer-specific mortality) than the control group (Appendix D). In summary, the results from matching propensity score analysis were not different from regression analysis in both short-term and long-term outcomes. In subgroup analysis in patients age !70 years, adverse prognostic factors for long-term cancer specific mortality were having universal coverage scheme, presence of intratumoral lymphatic invasion, presence of perineural invasion, undergoing pneumonectomy (compared to lobectomy), not undergo systematic lymph node dissection, not receiving adjuvant chemotherapy (in stage II and III disease after surgery) and higher stage of disease (Table 5 ).
Discussion
Pulmonary resection with or without mediastinal lymph node sampling or dissection is commonly accepted as the standard treatment of choice for early or local NSCLC patients; however, previous studies demonstrated that surgery rate in elderly patients is lower than in younger ages (4.9% versus 17.7%). 4 This may be due to a combination of poor medical and physiological status in elderly patients, which could be responsible for the higher postoperative morbidity and mortality. 22 Moreover, impairment of immune response in elderly patients may lead to postoperative complications such as respiratory tract infections. 23 The present study found that some clinical characteristics were different between patient age !70 years and age <70 years such as the incidence of COPD, hypertension, dyslipidemia, abnormal ECG, and number of pack-years of smoking. This difference may explain by age-related difference occurs in the general population, 24 not only in the analyzed groups operated for NSCLC. For postoperative outcomes in NSCLC patients between the study group and the control group patients, shows no statistically significant differences in term of POM between the two groups. Therefore, patients age !70 years seem to have no increased risk of postoperative complications compared to patients age <70 years, except for the incidence of postoperative acute renal failure. This difference may be explained by the decline in glomerular filtrate rate in elderly patients. 25 The incidence of in-hospital mortality in our cohort was 1.9% (11 in 583): 4.2% for study group and 1.0% for control group, which was comparable to the result of a recent study by Detillon et al. 26 The operative mortality in their cohort was 2.1%: 2.6% for patients aged 70e79 years and 1.0% for patients aged 60e69 years. Similar to our study, they also found that there was no statistically significant difference in the incidence of postoperative complications between the two groups. Ogawa et al 27 reported that lung cancer elderly patients (cut-off age of 75 years) were not at a significant higher risk for postoperative complications (OR Z 1.13, 95% CI Z 0.70e1.83). On the contrary, Liu et al 4 found that the postoperative hospital stay, comorbidities and mortality rates, and length in intensive care unit in elderly patients were significantly greater than in non-elderly patients. Unfortunately, this publication only present univariable analyses without any multivariable analysis results. In matching propensity score analysis of this study, ICU stay and in-hospital mortality in the study group were significantly greater than in the control group. However, there was no statistically significant differences in term of POM between the two groups, like showed in the regression method.
We found that sublobar resection was more frequent performed in study group with stage I disease, especially in stage IA3, however, in other stages, the proportion of patients who underwent sublobar and lobar resection was not statistically different between the two groups. The multivariable analysis showed that there was no significant difference in POM. This suggests that lobectomy is safe even in patients older than 70 years. Previous studies stated that sublobar resection might achieve similar long-term survival compared to lobectomy in elderly patients, especially those with low %FEV1 and tumor less than 2 cm. However, Zhang et al stated that elder age alone could not be used to select patients for sublobar resection in early stage NSCLC because older patients tend to have worse overall survival and lung cancer-specific survival. 32 Recently, Yang et al 33 have developed a prospective randomized controlled multicenter non-inferiority trial to compare disease-free survival, peri-operative complications and mortality and overall survival between sublobar resection and lobectomy. The trial is still ongoing.
COPD was one of the risk factors included in the major complications and in-hospital mortality in the present study, similar to the study by Detillon et al. 26 However other studies 26, 27 found that other factors associated with operative morbidities and mortality are gender, being a smoker, FEV1% or DLCO % per 10% decrease, coronary artery bypass graft, congestive heart failure, high ECOG score (eastern cooperative oncology group) and resection more extensive than limited. We found that smoking status, % predicted FEV1, and pneumonectomy were significant risk factors for composite postoperative complications and inhospital mortality at the univariable analysis only. We attribute the results of previous studies to the small sample size causing lower statistical power.
There was no statistically significant difference in tumor recurrence between the two groups both in the univariable and multivariable analysis. However, this result is not conclusive because the median follow-up time in the study group was significantly shorter than in the control group (24 versus 34.1 months); therefore, a longer follow-up time is needed.
Patients in the study group were more likely to experience long-term cancer-specific mortality than those in the control group, similarly to what reported by previous studies. 27, 34 In study group, we found 7 adverse prognostic factors associated with long-term cancer-specific mortality: universal coverage scheme, presence of intratumoral lymphatic invasion, perineural invasion, undergoing pneumonectomy (compared with lobectomy), undergoing systematic lymph node sampling (compared with systematic lymph node dissection), not receiving adjuvant chemotherapy (in stage II and III disease after surgery) and higher stage of disease. In Thailand, targeted therapy (Epidermal growth factor receptor-Tyrosine kinase inhibitor) been approved for use as first-line therapy but patients must pay out of pocket. For second-line or third-line therapy, the reimbursement has been approved since 2012 but limited to the Civil Servant Medical Benefits Scheme under restricted criteria. The reimbursement did not cover in the universal coverage scheme or social security scheme. This may be the reason for shorter survival in patients with universal coverage scheme or social security insurance scheme. Intratumoral lymphatic invasion and perineural invasion were reported as adverse prognostic factors for long-term cancer-specific mortality in previous studies, 35e37 however, these factors were not studied as we did in the present study. Although patients in the study group undergoing pneumonectomy showed worse long-term survival than those undergoing lobectomy, the outcomes in the study group were similar to the control group in terms of POM. This suggests that patients should not be denied pneumonectomy based on age alone. Very careful selection of elderly patients is essential in order to optimize survival and quality of life, as reported by previous studies. 38, 39 Because there were only 2 patients (1.87%) in the study group who underwent pneumonectomy and both of them died, the adjusted hazard ratio was overestimated with very wide 95% confidence interval. Therefore, the association between pneumonectomy and overall survival could not be assessed in this study. However, pneumonectomy would have poorer survival because tumor stage was more advance and quality of life was certainly worse. 40 Previous studies demonstrated that systematic lymph node dissection (radical dissection) in patients age ! 70 years resulted in increased postoperative pulmonary complications, shorter survival, and increase overall mortality. 41, 42 However, our study found that systematic lymph node dissection was associated with longer survival in comparison to lymph node sampling in study group. Further studies are needed to clarify this aspect. VATS approach is acceptable for non-elderly NSCLC patients; however, in elderly patients it is still controversial. Recent studies demonstrated that VATS approach was less invasive, had lower postoperative morbidity, shorter length of hospital stay than open thoracotomy, 43 however some studies stated that this approach is associated with higher postoperative complication rates. 44 Our result showed that VATS approach was associated with longer survival but not in a statistically significant manner, similar to previous studies. 45 Previous studies demonstrated that stage of disease was not significantly associated with overall survival in elderly patients, and that half of the elderly NSCLC patients (especially octogenarians) died of non-cancer related disease. 45, 46 However, our result showed that stage of disease was associated with long-term cancer-specific mortality in the multivariable analysis model. Although this study did not add anything new in the fields of lung cancer or VATS, the result of this study ensures that surgery in selected older patients is safe and the results comparable to what observed in younger patients. Furthermore, we can reassure or convince our patients who have indication or fit for adjuvant therapy which still have benefits on long-term survival in patients age >70 years, especially in patients who have adverse prognostic factors. Some patients and their relatives believe that they cannot tolerate the side effects of the drug because of old age.
This study has some limitations: it is retrospective in nature and single center. There are some selection biases for surgical procedures in elderly patients. Although there was no difference of pulmonary function between the two groups, sublobar resection was more likely to undergo in patients age !70 years. The reason may from other unrecorded comorbid diseases that may influence the decision of surgical procedures. However, this single-center data set is built in a systematic way with a good data recording system, therefore, the missing data in each variable of this study is less than 5%, except for pulmonary function test (15% of missing data). In addition, we used multiple imputations to address missing data, and presented multivariable analyses to analyze the data in a more comprehensive way in comparison to previous papers on this topic. 4 
Conclusion
Postoperative morbidity and in-hospital mortality for pulmonary resection in NSCLC patients age !70 years were acceptable and comparable to what observed in patients age <70 years. Disease-free survival was not different between groups, however, patients age !70 years had shorter long-term survival than patients age <70 years. In the subgroup of patients age !70 years, there were 7 adverse prognostic factors for long-term cancer-specific mortality; UCS coverage, presence of intratumoral lymphatic invasion, perineural invasion, higher stage of disease, underwent pneumonectomy, underwent systematic lymph node sampling, and not receiving adjuvant chemotherapy. Therefore, systematic lymph node dissection should be performed rather than lymph node sampling. Patients age !70 years presenting with intratumoral lymphatic invasion or perineural invasion should be further considered for possible adjuvant chemotherapy. Effect of insurance coverage on lung cancer survival should be explored in future studies. Further studies with larger sample size are warranted.
